The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) jointly announce that the Accelerating Drug Discovery for Frontotemporal Degeneration RFP is now accepting letters of intent.
There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD) and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). Drug targets in the areas of inflammation and proteostasis will be considered high priority. The average duration of the award is one year with potential for follow-on funding, and the average award amount is $100,000-$150,000 based on stage and scope of research.
Funding is open to researchers and clinicians in the U.S. and worldwide working in:
- Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
- Biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.
Please review our Funding Policies before applying.
Letter of Intent: May 28th, 2021
Invited Full Proposal: July 30th, 2021